| abstract |
A combination kit for the treatment of malaria caused by Plasmodium vivax (P . vivax) having individual doses of an anti-malarial agent, 3-[1-[[4-[(6-metho xy- 8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I) in th e form of capsules; individual doses of the anti-malarial agent, chloroquine i n the form of tablets; and instruction material for the administration of the two anti-malarial drugs. The combination kit is particularly suited for a 6 days treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent to 300 mg base), thre e to be taken on day one and one each on days two and three; and five capsules containing 25 mg of 3-[1-[[4-[(6-methoxy-8- quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I), one ea ch to be taken on days two to six. |